Skip to main content

Vanderbilt Team Will Use Affy Arrays to Study HIV/AIDS, Cancer\

NEW YORK (GenomeWeb News) — The Vanderbilt-Ingram Cancer Center will use Affymetrix’s GeneChip microarrays in translational research projects studying cancer and HIV and AIDS, Affy said today.
 
Under the terms of the agreement, VICC and Vanderbilt University Medical Center will use Affy’s mitochondrial resequencing array 2.0 as a tool to research genetic variants that may make patients more susceptible to adverse effects of certain drugs.
 
For cancer, Affy said VICC hopes that the studies will reveal the molecular basis of diseases and differences at the genetic level that influence responses to therapies. For HIV/AIDS research, the study aims to help clinicians determine the best drug treatments in “affluent and resource-limited settings.”
 
Jeff Canter, a researcher at the Center for Human Genetics Research and Vanderbilt, said ongoing translational projects include cancer, HIV/AIDS drug toxicities,” and macular degeneration.
 
Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.